董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Arthur O. Tzianabos | 男 | Chair of the Board and Independent Director | 61 | 77.88万美元 | 13.38 | 2025-10-06 |
| Adrian R. Krainer | 男 | Director | 66 | 26.83万美元 | 55.07 | 2025-10-06 |
| Arthur Levin | 男 | Director | 71 | 28.12万美元 | 13.21 | 2025-10-06 |
| Seth L. Harrison | 男 | Director | 64 | 27.08万美元 | 197.17 | 2025-10-06 |
| Jennifer C. Burstein | 女 | Director | 53 | 28.33万美元 | 9.64 | 2025-10-06 |
| Garry E. Menzel | 男 | Director | 60 | 28.08万美元 | 8.16 | 2025-10-06 |
| Ian F. Smith | 男 | Chief Executive Officer and Director | 59 | 2703.17万美元 | 8.79 | 2025-10-06 |
| Edward M. Kaye | 男 | Director | 76 | 323.40万美元 | 188.80 | 2025-10-06 |
| Julie Anne Smith | 女 | Director | 54 | 28.33万美元 | 8.16 | 2025-10-06 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Barry S. Ticho | -- | Chief Medical Officer | 65 | 246.94万美元 | 24.52 | 2025-10-06 |
| Thomas E. Leggett | 男 | Chief Financial Officer | 48 | 183.04万美元 | 10.28 | 2025-10-06 |
| Jonathan Allan | 男 | General Counsel and Corporate Secretary | 35 | 未披露 | 未持股 | 2025-10-06 |
| Ian F. Smith | 男 | Chief Executive Officer and Director | 59 | 2703.17万美元 | 8.79 | 2025-10-06 |
董事简历
中英对照 | 中文 | 英文- Arthur O. Tzianabos
-
ArthurO.Tzianabos博士自2016年4月起担任我们的总裁，首席执行官兼董事会成员。Tzianabos博士从Ovascience，Inc.加入Homology，Ovascience，Inc.是一家生物技术公司，此后与MillendoTherapeutics，Inc.合并，他于2013年9月至2016年3月担任总裁兼首席科学官。任职Ovascience公司之前，Tzianabos博士曾在Shire plc（一家生物技术公司）任职8年，在那里他担任越来越重要的职务，包括发现研究、Vice President、项目管理和高级副总裁高级主管以及研究和早期开发主管。Tzianabos从1992年到2005年担任Harvard Medical School教员，在Channing Laboratory，Brigham and Women&8217；s Hospital以及Harvard Medical School微生物和分子遗传学系维护实验室。Tzianabos博士目前担任StokeTherapeutics，Inc.的董事Tzianabos博士曾担任BindTherapeutics，Inc.公司的董事。Tzianabos博士拥有波士顿学院（Boston College）生物学学士学位和新罕布什尔大学（University of New Hampshire）微生物学博士学位。
Arthur O. Tzianabos,spent eight years at Shire plc, a biotechnology company, where he served in positions of increasing responsibility, including Senior Director, Discovery Research, Vice President, Program Management and Senior Vice President and Head, Research and Early Development. From 1992 to 2005, Dr. Tzianabos was a faculty member at Harvard Medical School and maintained laboratories at the Channing Laboratory, Brigham and Women's Hospital and the Department of Microbiology and Molecular Genetics at Harvard Medical School. Dr. Tzianabos has served as chairman and a director of Stoke Therapeutics, Inc. (NASDAQ: STOK), a public biotechnology company, since April 2018. Dr. Tzianabos previously served as chairman of the board of directors of Akouos, Inc., a public biotechnology company, from July 2018 until its acquisition by Eli Lilly in December 2022, and a director of BIND Therapeutics, Inc., a biotechnology company, from October 2015 until its acquisition by Pfizer in July 2016. Dr. Tzianabos holds a B.S. in Biology from Boston College and a Ph.D. in Microbiology from the University of New Hampshire, and completed a Post-Doctoral Fellowship in Immunology at Harvard Medical School. - ArthurO.Tzianabos博士自2016年4月起担任我们的总裁，首席执行官兼董事会成员。Tzianabos博士从Ovascience，Inc.加入Homology，Ovascience，Inc.是一家生物技术公司，此后与MillendoTherapeutics，Inc.合并，他于2013年9月至2016年3月担任总裁兼首席科学官。任职Ovascience公司之前，Tzianabos博士曾在Shire plc（一家生物技术公司）任职8年，在那里他担任越来越重要的职务，包括发现研究、Vice President、项目管理和高级副总裁高级主管以及研究和早期开发主管。Tzianabos从1992年到2005年担任Harvard Medical School教员，在Channing Laboratory，Brigham and Women&8217；s Hospital以及Harvard Medical School微生物和分子遗传学系维护实验室。Tzianabos博士目前担任StokeTherapeutics，Inc.的董事Tzianabos博士曾担任BindTherapeutics，Inc.公司的董事。Tzianabos博士拥有波士顿学院（Boston College）生物学学士学位和新罕布什尔大学（University of New Hampshire）微生物学博士学位。
- Arthur O. Tzianabos,spent eight years at Shire plc, a biotechnology company, where he served in positions of increasing responsibility, including Senior Director, Discovery Research, Vice President, Program Management and Senior Vice President and Head, Research and Early Development. From 1992 to 2005, Dr. Tzianabos was a faculty member at Harvard Medical School and maintained laboratories at the Channing Laboratory, Brigham and Women's Hospital and the Department of Microbiology and Molecular Genetics at Harvard Medical School. Dr. Tzianabos has served as chairman and a director of Stoke Therapeutics, Inc. (NASDAQ: STOK), a public biotechnology company, since April 2018. Dr. Tzianabos previously served as chairman of the board of directors of Akouos, Inc., a public biotechnology company, from July 2018 until its acquisition by Eli Lilly in December 2022, and a director of BIND Therapeutics, Inc., a biotechnology company, from October 2015 until its acquisition by Pfizer in July 2016. Dr. Tzianabos holds a B.S. in Biology from Boston College and a Ph.D. in Microbiology from the University of New Hampshire, and completed a Post-Doctoral Fellowship in Immunology at Harvard Medical School.
- Adrian R. Krainer
-
AdrianR.Krainer联合创立了StokeTherapeutics，Inc.，自2014年6月以来一直担任我们的董事会成员。Krainer教授是Cold Spring Harbor Laboratory（一家生物研究机构）的St.Giles教授，他自1986年以来一直在那里任职，他的工作直接导致Spinraza的发明和发展。Krainer教授拥有哥伦比亚大学（Columbia University）生物化学学士学位和哈佛大学（Harvard University）生物化学博士学位。
Adrian R. Krainer,is the St. Giles Professor at Cold Spring Harbor Laboratory, a biological research institution, where he has served since 1986 and where his work led directly to the invention and development of SPINRAZA. Professor Krainer holds a B.A. in Biochemistry from Columbia University and a Ph.D. in Biochemistry from Harvard University. - AdrianR.Krainer联合创立了StokeTherapeutics，Inc.，自2014年6月以来一直担任我们的董事会成员。Krainer教授是Cold Spring Harbor Laboratory（一家生物研究机构）的St.Giles教授，他自1986年以来一直在那里任职，他的工作直接导致Spinraza的发明和发展。Krainer教授拥有哥伦比亚大学（Columbia University）生物化学学士学位和哈佛大学（Harvard University）生物化学博士学位。
- Adrian R. Krainer,is the St. Giles Professor at Cold Spring Harbor Laboratory, a biological research institution, where he has served since 1986 and where his work led directly to the invention and development of SPINRAZA. Professor Krainer holds a B.A. in Biochemistry from Columbia University and a Ph.D. in Biochemistry from Harvard University.
- Arthur Levin
-
ArthurA.Levin自2015年9月以来一直担任我们的董事会成员。自2014年1月起，Levin博士担任Avidity Biosciences LLC（一家生物技术公司）研究与开发的执行Vice President。2012年4月至2014年1月，Levin博士担任RNA治疗公司MiragenTherapeutics，Inc.的执行Vice President。在加入MiragenTherapeutics，Inc.之前，Levin博士曾在生物制药公司Santaris Pharma A/S Corp.和专注于RNA的上市生物制药公司伊奥尼斯制药公司担任多个高级管理职位。Levin博士拥有Muhlenberg College生物学学士学位和the University of Rochester毒理学博士学位。
Arthur Levin has served on board of directors since February 2023. Dr. Levin served as Distinguished Scientist and Strategic Leader from February 2023 until the end of 2024 after serving as Chief Scientific Officer from October 2019 to February 2023. Previoly, Dr. Levin served as Executive Vice President of Research and Development from October 2013 to October 2019. Dr. Levin has a combined three decades of experience in all aspects of drug development from discovery through drug registration and has played key roles in the development of numero oligonucleotides. Prior to joining Avidity, from April 2012 to January 2014, he served as Executive Vice President at miRagen Therapeutics, Inc. Prior to that, Dr. Levin held vario senior management positions at Santaris Pharma A/S Corp. and Ionis Pharmaceuticals, Inc. Since September 2015, Dr. Levin has served as a member of the board of directors of Stoke Therapeutics, Inc. Dr. Levin holds a Ph.D. in Toxicology from the University of Rochester and a B.S. in Biology from Muhlenberg College. Dr. Levin's knowledge of biness and technology and his extensive drug development experience contributed to board of directors' conclion that he should serve as a director of company. - ArthurA.Levin自2015年9月以来一直担任我们的董事会成员。自2014年1月起，Levin博士担任Avidity Biosciences LLC（一家生物技术公司）研究与开发的执行Vice President。2012年4月至2014年1月，Levin博士担任RNA治疗公司MiragenTherapeutics，Inc.的执行Vice President。在加入MiragenTherapeutics，Inc.之前，Levin博士曾在生物制药公司Santaris Pharma A/S Corp.和专注于RNA的上市生物制药公司伊奥尼斯制药公司担任多个高级管理职位。Levin博士拥有Muhlenberg College生物学学士学位和the University of Rochester毒理学博士学位。
- Arthur Levin has served on board of directors since February 2023. Dr. Levin served as Distinguished Scientist and Strategic Leader from February 2023 until the end of 2024 after serving as Chief Scientific Officer from October 2019 to February 2023. Previoly, Dr. Levin served as Executive Vice President of Research and Development from October 2013 to October 2019. Dr. Levin has a combined three decades of experience in all aspects of drug development from discovery through drug registration and has played key roles in the development of numero oligonucleotides. Prior to joining Avidity, from April 2012 to January 2014, he served as Executive Vice President at miRagen Therapeutics, Inc. Prior to that, Dr. Levin held vario senior management positions at Santaris Pharma A/S Corp. and Ionis Pharmaceuticals, Inc. Since September 2015, Dr. Levin has served as a member of the board of directors of Stoke Therapeutics, Inc. Dr. Levin holds a Ph.D. in Toxicology from the University of Rochester and a B.S. in Biology from Muhlenberg College. Dr. Levin's knowledge of biness and technology and his extensive drug development experience contributed to board of directors' conclion that he should serve as a director of company.
- Seth L. Harrison
-
SethL.Harrison自2015年7月以来一直担任我们的董事会主席。他曾担任Apple Tree Partners公司（风险投资公司，他于1999年创立）的管理合伙人。创立Apple Tree Partners公司之前，Harrison博士曾担任Oak Investment Partners公司（一家风险投资和私募股权公司）的普通合伙人，以及Sevin Rosen Funds公司（一家技术风险投资公司）的风险合伙人。哈里森博士目前担任制药公司BraeburnPharmaceuticals，Inc.、免疫治疗公司Elstar Therapeutics，Inc.、基因治疗公司Limelight Bio，Inc.以及几家私营公司的董事会主席。Harrison博士拥有普林斯顿大学（Princeton University）的A.B.和哥伦比亚大学（Columbia University）的M.D.和M.B.A.。
Seth L. Harrison,serves as Managing Partner at Apple Tree Partners, a venture capital firm, which he founded in 1999. Prior to founding Apple Tree Partners, Dr. Harrison served as a General Partner at Oak Investment Partners, a venture capital and private equity firm, and as a Venture Partner at Sevin Rosen Funds, a technology-focused venture capital firm. Dr. Harrison currently serves as a member of the board of directors of Akero Therapeutics, Inc., a public biopharmaceutical company. Dr. Harrison also serves as the chair of the boards of directors of Braeburn Inc., a pharmaceutical company, Marengo Therapeutics, Inc., an immunotherapy company, and Galvanize Therapeutics, Inc., a medical device company, as well as a director for numerous other private companies. Dr. Harrison holds an A.B. from Princeton University and an M.D. and M.B.A. from Columbia University. - SethL.Harrison自2015年7月以来一直担任我们的董事会主席。他曾担任Apple Tree Partners公司（风险投资公司，他于1999年创立）的管理合伙人。创立Apple Tree Partners公司之前，Harrison博士曾担任Oak Investment Partners公司（一家风险投资和私募股权公司）的普通合伙人，以及Sevin Rosen Funds公司（一家技术风险投资公司）的风险合伙人。哈里森博士目前担任制药公司BraeburnPharmaceuticals，Inc.、免疫治疗公司Elstar Therapeutics，Inc.、基因治疗公司Limelight Bio，Inc.以及几家私营公司的董事会主席。Harrison博士拥有普林斯顿大学（Princeton University）的A.B.和哥伦比亚大学（Columbia University）的M.D.和M.B.A.。
- Seth L. Harrison,serves as Managing Partner at Apple Tree Partners, a venture capital firm, which he founded in 1999. Prior to founding Apple Tree Partners, Dr. Harrison served as a General Partner at Oak Investment Partners, a venture capital and private equity firm, and as a Venture Partner at Sevin Rosen Funds, a technology-focused venture capital firm. Dr. Harrison currently serves as a member of the board of directors of Akero Therapeutics, Inc., a public biopharmaceutical company. Dr. Harrison also serves as the chair of the boards of directors of Braeburn Inc., a pharmaceutical company, Marengo Therapeutics, Inc., an immunotherapy company, and Galvanize Therapeutics, Inc., a medical device company, as well as a director for numerous other private companies. Dr. Harrison holds an A.B. from Princeton University and an M.D. and M.B.A. from Columbia University.
- Jennifer C. Burstein
-
JenniferC.Burstein自2019年6月以来一直担任我们的董事会成员。从2018年1月至2019年2月，Burstein女士担任生物技术公司LoxoOncology，Inc.的财务高级副总裁兼首席财务官，直到该公司被礼来公司收购。Burstein女士自2015年5月起曾担任Loxo Oncology财务Vice President和首席财务官。在加入Loxo Oncology之前，Burstein女士于2010年7月至2015年4月担任AcordaTherapeutics，Inc.（一家上市生物技术公司）的财务Vice President，从2006年到被任命为财务Vice President，她在该公司担任了多个财务职责递增的职位。加入Acorda公司之前，她曾任职Eyetech Pharmaceuticals公司（上市生物技术公司，目前是Valeant Pharmaceuticals International公司的子公司），在那里她曾担任多种财务职务，并不断被提拔为高级会计董事（从2002年到2006年）。在Eyetech之前，Burstein女士曾在几家公司的财务部门和公共会计部门工作。Burstein女士在纽约州立大学布法罗分校（State University of New York at Buffalo）获得工商管理学士学位和会计学工商管理硕士学位，并在纽约获得注册会计师执照。
Jennifer C. Burstein,has served as Senior Vice President – Finance Operations at Treeline Biosciences, Inc., a biotechnology company. From January 2018 to February 2019, Ms. Burstein served as Senior Vice President of Finance and principal financial officer at Loxo Oncology, Inc., a biotechnology company, until its acquisition by Eli Lilly and Company. Ms. Burstein previously served as Vice President of Finance and principal financial officer of Loxo Oncology since May 2015. Prior to Loxo Oncology, Ms. Burstein served as Vice President of Finance at Acorda Therapeutics, Inc., a public biotechnology company, from July 2010 until April 2015, where she held several positions of increasing responsibility in Finance from 2006 until being appointed Vice President of Finance. Prior to joining Acorda, from 2002 to 2006, she was with Eyetech Pharmaceuticals, Inc., a public biotechnology company, now a subsidiary of Valeant Pharmaceuticals International, Inc., where she held several positions of increasing responsibility in Finance until being promoted to Senior Director, Accounting. Ms. Burstein received her B.S. in Business Administration and M.B.A. in Accounting from the State University of New York at Buffalo and has a CPA license in New York. - JenniferC.Burstein自2019年6月以来一直担任我们的董事会成员。从2018年1月至2019年2月，Burstein女士担任生物技术公司LoxoOncology，Inc.的财务高级副总裁兼首席财务官，直到该公司被礼来公司收购。Burstein女士自2015年5月起曾担任Loxo Oncology财务Vice President和首席财务官。在加入Loxo Oncology之前，Burstein女士于2010年7月至2015年4月担任AcordaTherapeutics，Inc.（一家上市生物技术公司）的财务Vice President，从2006年到被任命为财务Vice President，她在该公司担任了多个财务职责递增的职位。加入Acorda公司之前，她曾任职Eyetech Pharmaceuticals公司（上市生物技术公司，目前是Valeant Pharmaceuticals International公司的子公司），在那里她曾担任多种财务职务，并不断被提拔为高级会计董事（从2002年到2006年）。在Eyetech之前，Burstein女士曾在几家公司的财务部门和公共会计部门工作。Burstein女士在纽约州立大学布法罗分校（State University of New York at Buffalo）获得工商管理学士学位和会计学工商管理硕士学位，并在纽约获得注册会计师执照。
- Jennifer C. Burstein,has served as Senior Vice President – Finance Operations at Treeline Biosciences, Inc., a biotechnology company. From January 2018 to February 2019, Ms. Burstein served as Senior Vice President of Finance and principal financial officer at Loxo Oncology, Inc., a biotechnology company, until its acquisition by Eli Lilly and Company. Ms. Burstein previously served as Vice President of Finance and principal financial officer of Loxo Oncology since May 2015. Prior to Loxo Oncology, Ms. Burstein served as Vice President of Finance at Acorda Therapeutics, Inc., a public biotechnology company, from July 2010 until April 2015, where she held several positions of increasing responsibility in Finance from 2006 until being appointed Vice President of Finance. Prior to joining Acorda, from 2002 to 2006, she was with Eyetech Pharmaceuticals, Inc., a public biotechnology company, now a subsidiary of Valeant Pharmaceuticals International, Inc., where she held several positions of increasing responsibility in Finance until being promoted to Senior Director, Accounting. Ms. Burstein received her B.S. in Business Administration and M.B.A. in Accounting from the State University of New York at Buffalo and has a CPA license in New York.
- Garry E. Menzel
-
Garry E. Menzel于2016年加入Tcr2 Therapeutics Inc.，担任Tcr2 Therapeutics Inc.董事兼首席执行官。Menzel博士自2014年起担任肿瘤公司Black Diamond Therapeutics Inc.的董事会和审计委员会主席，Menzel博士于2015年至2016年担任Axcella Health Inc.的首席战略官，2013年至2015年担任DaVita Healthcare Partners Inc.的首席财务官，2008年至2013年担任Regulus Therapeutics Inc.的首席运营官。Menzel博士在高盛和1994年至2004年为Co.LLC，2004年至2008年为Credit Suisse Group AG。此外，他还是贝恩公司的顾问，也是史克比彻姆公司（SmithKline Beecham PLC）现在的葛兰素史克公司（GlaxoSmithKline PLC）的研究助理。门泽尔博士获得了博士学位。来自剑桥大学，他在那里研究了免疫细胞癌基因的调节，以及他的斯坦福大学工商管理研究生院的M.B.A.。
Garry E. Menzel joined our company in 2016 as a director and Chief Executive Officer. Dr. Menzel has also served on the board of directors and chairman of the audit committee of the oncology company Black Diamond Therapeutics Inc. since 2014. Previously, Dr. Menzel was the Chief Strategy Officer at Axcella Health Inc. from 2015 to 2016 the Chief Financial Officer at DaVita Healthcare Partners Inc. from 2013 to 2015 and the Chief Operating Officer at Regulus Therapeutics Inc. from 2008 to 2013. Dr. Menzel also had global leadership roles in running the biotechnology practices at Goldman Sachs & Co. LLC from 1994 to 2004 and Credit Suisse Group AG from 2004 to 2008. In addition, he was a consultant with Bain & Company and was a research assistant at SmithKline Beecham PLC now GlaxoSmithKline PLC. Dr. Menzel received his Ph.D. from the University of Cambridge, where he studied the regulation of oncogenes in immune cells, and his M.B.A. from the Stanford University Graduate School of Business. - Garry E. Menzel于2016年加入Tcr2 Therapeutics Inc.，担任Tcr2 Therapeutics Inc.董事兼首席执行官。Menzel博士自2014年起担任肿瘤公司Black Diamond Therapeutics Inc.的董事会和审计委员会主席，Menzel博士于2015年至2016年担任Axcella Health Inc.的首席战略官，2013年至2015年担任DaVita Healthcare Partners Inc.的首席财务官，2008年至2013年担任Regulus Therapeutics Inc.的首席运营官。Menzel博士在高盛和1994年至2004年为Co.LLC，2004年至2008年为Credit Suisse Group AG。此外，他还是贝恩公司的顾问，也是史克比彻姆公司（SmithKline Beecham PLC）现在的葛兰素史克公司（GlaxoSmithKline PLC）的研究助理。门泽尔博士获得了博士学位。来自剑桥大学，他在那里研究了免疫细胞癌基因的调节，以及他的斯坦福大学工商管理研究生院的M.B.A.。
- Garry E. Menzel joined our company in 2016 as a director and Chief Executive Officer. Dr. Menzel has also served on the board of directors and chairman of the audit committee of the oncology company Black Diamond Therapeutics Inc. since 2014. Previously, Dr. Menzel was the Chief Strategy Officer at Axcella Health Inc. from 2015 to 2016 the Chief Financial Officer at DaVita Healthcare Partners Inc. from 2013 to 2015 and the Chief Operating Officer at Regulus Therapeutics Inc. from 2008 to 2013. Dr. Menzel also had global leadership roles in running the biotechnology practices at Goldman Sachs & Co. LLC from 1994 to 2004 and Credit Suisse Group AG from 2004 to 2008. In addition, he was a consultant with Bain & Company and was a research assistant at SmithKline Beecham PLC now GlaxoSmithKline PLC. Dr. Menzel received his Ph.D. from the University of Cambridge, where he studied the regulation of oncogenes in immune cells, and his M.B.A. from the Stanford University Graduate School of Business.
- Ian F. Smith
-
Ian F. Smith，是一位经验丰富的领导者，拥有30多年的金融和运营经验。Smith先生目前担任Rivus Pharmaceutical Inc.的董事会主席，他自2023年11月以来一直担任该职位。Smith先生还担任贝恩资本生命科学公司的高级顾问（自2021年1月起担任该职位），以及自2020年6月起担任Solid Biosciences Inc.（纳斯达克：SLDB）董事会执行主席。他还自2021年4月起担任Foghorn Therapeutics Inc.（纳斯达克：FHTX）的董事会成员，并自2023年9月起担任Stoke Therapeutics, Inc.（纳斯达克：STOK）的董事会成员。在担任现任职务之前，Smith先生曾于2019年7月至2022年9月担任私营生物技术公司Viacyte的董事会执行主席。Smith先生此前曾于2001年至2019年1月在福泰制药担任过多个职务，包括首席财务官和首席运营官。在加入福泰制药之前，Smith先生是会计师事务所Ernst & Young LLP的合伙人，为私营和上市公司提供服务，包括生物技术公司。Smith先生还担任多家私营生物技术公司的董事会成员，并提供咨询服务。
Ian F. Smith has served as a member of Odyssey Therapeutics, Inc.'s board of directors since August 2024 and prior to that as a consultant. Mr. Smith is an experienced leader with more than 30 years of finance and operating experience. Mr. Smith has served as Chief Executive Officer of Stoke Therapeutics, Inc. (Nasdaq: STOK) since October 2025 and a member of the board of directors since 2023, and previously served as Interim Chief Executive Officer from March 2025 to October 2025. In addition, Mr. Smith is the Chair of the board of directors for Rivus Pharmaceutical Inc., a position he has held since November 2023. Mr. Smith also serves as a Senior Advisor to Bain Capital Life Sciences, which position he has held since January 2021, and as Executive Chair of the board of directors of Solid Biosciences Inc. (Nasdaq: SLDB), which position he has held since June 2020. He has also served as a member of the board of directors of Foghorn Therapeutics Inc. (Nasdaq: FHTX) since April 2021. Prior to his current roles, Mr. Smith served as Executive Chair of the board of directors of Viacyte, a private biotechnology company, from July 2019 to September 2022. Mr. Smith previously served in various roles at Vertex from 2001 until January 2019, including as the Chief Financial Officer and Chief Operating Officer. Prior to joining Vertex, Mr. Smith was a partner of the accounting firm Ernst & Young LLP, serving private and public companies, including biotechnology companies. Mr. Smith also serves on the boards of a number of private biotechnology companies and provides advisory services. Mr. Smith holds a B.A. with honors in accounting and finance from Manchester Metropolitan University (UK). - Ian F. Smith，是一位经验丰富的领导者，拥有30多年的金融和运营经验。Smith先生目前担任Rivus Pharmaceutical Inc.的董事会主席，他自2023年11月以来一直担任该职位。Smith先生还担任贝恩资本生命科学公司的高级顾问（自2021年1月起担任该职位），以及自2020年6月起担任Solid Biosciences Inc.（纳斯达克：SLDB）董事会执行主席。他还自2021年4月起担任Foghorn Therapeutics Inc.（纳斯达克：FHTX）的董事会成员，并自2023年9月起担任Stoke Therapeutics, Inc.（纳斯达克：STOK）的董事会成员。在担任现任职务之前，Smith先生曾于2019年7月至2022年9月担任私营生物技术公司Viacyte的董事会执行主席。Smith先生此前曾于2001年至2019年1月在福泰制药担任过多个职务，包括首席财务官和首席运营官。在加入福泰制药之前，Smith先生是会计师事务所Ernst & Young LLP的合伙人，为私营和上市公司提供服务，包括生物技术公司。Smith先生还担任多家私营生物技术公司的董事会成员，并提供咨询服务。
- Ian F. Smith has served as a member of Odyssey Therapeutics, Inc.'s board of directors since August 2024 and prior to that as a consultant. Mr. Smith is an experienced leader with more than 30 years of finance and operating experience. Mr. Smith has served as Chief Executive Officer of Stoke Therapeutics, Inc. (Nasdaq: STOK) since October 2025 and a member of the board of directors since 2023, and previously served as Interim Chief Executive Officer from March 2025 to October 2025. In addition, Mr. Smith is the Chair of the board of directors for Rivus Pharmaceutical Inc., a position he has held since November 2023. Mr. Smith also serves as a Senior Advisor to Bain Capital Life Sciences, which position he has held since January 2021, and as Executive Chair of the board of directors of Solid Biosciences Inc. (Nasdaq: SLDB), which position he has held since June 2020. He has also served as a member of the board of directors of Foghorn Therapeutics Inc. (Nasdaq: FHTX) since April 2021. Prior to his current roles, Mr. Smith served as Executive Chair of the board of directors of Viacyte, a private biotechnology company, from July 2019 to September 2022. Mr. Smith previously served in various roles at Vertex from 2001 until January 2019, including as the Chief Financial Officer and Chief Operating Officer. Prior to joining Vertex, Mr. Smith was a partner of the accounting firm Ernst & Young LLP, serving private and public companies, including biotechnology companies. Mr. Smith also serves on the boards of a number of private biotechnology companies and provides advisory services. Mr. Smith holds a B.A. with honors in accounting and finance from Manchester Metropolitan University (UK).
- Edward M. Kaye
-
Edward M. Kaye，自2017年10月起担任Stoke Therapeutics, Inc.董事会成员，还于2017年10月至2025年3月期间担任Stoke Therapeutics, Inc.首席执行官。他从医疗研究和药物开发公司Sarepta Therapeutics, Inc.加入Stoke Therapeutics，曾于2016年9月至2017年7月担任总裁兼首席执行官，2015年4月至2016年9月担任临时首席执行官，2011年6月至2017年3月担任首席医疗官。从2001年到2011年，Kaye博士曾在生物技术公司Genzyme Corporation担任多个职位，包括最近担任集团临床开发副总裁。此前，Kaye博士曾担任Philadelphia儿童医院生化遗传学主任、St. Christopher儿童医院神经内科主任，以及Massachusetts General Hospital and Tufts University Medical Center的研究人员。Kaye医生目前在波士顿儿童医院担任神经学顾问。Kaye博士还是一家上市生物制药公司Cytokinetics公司、一家上市生物技术公司Avidity Biosciences公司以及一家私营非营利性生命科学行业组织Massachusetts Biotechnology Council的董事会成员。Kaye博士拥有Loyola大学的生物学/化学学士学位和Loyola大学Stritch医学院的医学博士学位。
Edward M. Kaye,has served as a member of Stoke Therapeutics, Inc. Board of Directors since October 2017 and also served as Stoke Therapeutics, Inc. Chief Executive Officer from October 2017 to March 2025. He joined Stoke Therapeutics, Inc. from Sarepta Therapeutics, Inc., a medical research and drug development company, where he served as President and Chief Executive Officer from September 2016 to July 2017, Interim Chief Executive Officer from April 2015 to September 2016 and Chief Medical Officer from June 2011 to March 2017. From 2001 to 2011, Dr. Kaye served in various positions at Genzyme Corporation, a biotechnology company, including most recently as Group Vice President of Clinical Development. Previously, Dr. Kaye served as Chief of Biochemical Genetics at Children's Hospital of Philadelphia, Chief of Neurology at St. Christopher's Hospital for Children, and as a member of the research staff at Massachusetts General Hospital and Tufts University Medical Center. Dr. Kaye currently serves as a Neurological Consultant at the Children's Hospital of Boston. Dr. Kaye is also a member of the boards of directors of Cytokinetics, Inc., a public biopharmaceutical company, Avidity Biosciences, Inc. a public biotechnology company, and the Massachusetts Biotechnology Council, a private non-profit life sciences industry organization. Dr. Kaye holds a B.S. in Biology/Chemistry from Loyola University and a M.D. from the Loyola University Stritch School of Medicine. - Edward M. Kaye，自2017年10月起担任Stoke Therapeutics, Inc.董事会成员，还于2017年10月至2025年3月期间担任Stoke Therapeutics, Inc.首席执行官。他从医疗研究和药物开发公司Sarepta Therapeutics, Inc.加入Stoke Therapeutics，曾于2016年9月至2017年7月担任总裁兼首席执行官，2015年4月至2016年9月担任临时首席执行官，2011年6月至2017年3月担任首席医疗官。从2001年到2011年，Kaye博士曾在生物技术公司Genzyme Corporation担任多个职位，包括最近担任集团临床开发副总裁。此前，Kaye博士曾担任Philadelphia儿童医院生化遗传学主任、St. Christopher儿童医院神经内科主任，以及Massachusetts General Hospital and Tufts University Medical Center的研究人员。Kaye医生目前在波士顿儿童医院担任神经学顾问。Kaye博士还是一家上市生物制药公司Cytokinetics公司、一家上市生物技术公司Avidity Biosciences公司以及一家私营非营利性生命科学行业组织Massachusetts Biotechnology Council的董事会成员。Kaye博士拥有Loyola大学的生物学/化学学士学位和Loyola大学Stritch医学院的医学博士学位。
- Edward M. Kaye,has served as a member of Stoke Therapeutics, Inc. Board of Directors since October 2017 and also served as Stoke Therapeutics, Inc. Chief Executive Officer from October 2017 to March 2025. He joined Stoke Therapeutics, Inc. from Sarepta Therapeutics, Inc., a medical research and drug development company, where he served as President and Chief Executive Officer from September 2016 to July 2017, Interim Chief Executive Officer from April 2015 to September 2016 and Chief Medical Officer from June 2011 to March 2017. From 2001 to 2011, Dr. Kaye served in various positions at Genzyme Corporation, a biotechnology company, including most recently as Group Vice President of Clinical Development. Previously, Dr. Kaye served as Chief of Biochemical Genetics at Children's Hospital of Philadelphia, Chief of Neurology at St. Christopher's Hospital for Children, and as a member of the research staff at Massachusetts General Hospital and Tufts University Medical Center. Dr. Kaye currently serves as a Neurological Consultant at the Children's Hospital of Boston. Dr. Kaye is also a member of the boards of directors of Cytokinetics, Inc., a public biopharmaceutical company, Avidity Biosciences, Inc. a public biotechnology company, and the Massachusetts Biotechnology Council, a private non-profit life sciences industry organization. Dr. Kaye holds a B.S. in Biology/Chemistry from Loyola University and a M.D. from the Loyola University Stritch School of Medicine.
- Julie Anne Smith
-
Julie Anne Smith，她拥有近20年的生物技术，曾一直担任私人和公众持有的生物技术公司的执行管理职务，专注于孤儿药物开发和商业产品的机会。她曾担任Enobia Pharma公司（私营临床阶段孤儿药物公司，后来被Alexion收购）的首席商务官。从2006年8月到2008年7月，她曾负责商务，担任Jazz Pharmaceuticals公司的商业副总裁。从2001年12月到2006年8月，她曾担任Genzyme General公司（位于马萨诸塞州剑桥）的全球营销副总裁。她领导Myozyme公司（治疗一种超孤儿基因疾病的一个注入酶替代疗法）的全球商业化和计划。她持有康奈尔大学（ Cornell University ，位于纽约伊萨卡）的生物和营养科学的学士学位。
Julie Anne Smith was appointed as a director and the Chief Executive Officer of the Company, effective January 1 2015. Ms. Smith has also served as President of the Company since July 2014 and CEO-Designate from July 2014 to December 2014.She previously served as our Executive Vice President, Strategy and Chief Operating Officer from 2012 to 2014 where she was responsible for directing our commercial, manufacturing and program management organizations and providing leadership in corporate and strategic development initiatives. In her nearly 20 years in the biotechnology industry, Ms. Smith has served in executive management of both privately- and publicly-held biotechnology firms, mostly in orphan drug development and commercial product opportunities. Prior to joining us, from July 2008 to May 2012 Ms. Smith was Chief Commercial Officer of Enobia Pharma, Inc., a private, clinical-stage orphan drug company acquired by Alexion Pharmaceuticals. From August 2006 to July 2008 she led commercial functions as Vice President, Commercial at Jazz Pharmaceuticals. From December 2001 to August 2006 as Vice President, Global Marketing at Genzyme General in Cambridge, Massachusetts, she led the worldwide commercialization and planning for Myozyme, an infused enzyme replacement therapy for an ultra-orphan genetic disease. She holds a B.S. in Biological and Nutritional Science from Cornell University, Ithaca, New York. - Julie Anne Smith，她拥有近20年的生物技术，曾一直担任私人和公众持有的生物技术公司的执行管理职务，专注于孤儿药物开发和商业产品的机会。她曾担任Enobia Pharma公司（私营临床阶段孤儿药物公司，后来被Alexion收购）的首席商务官。从2006年8月到2008年7月，她曾负责商务，担任Jazz Pharmaceuticals公司的商业副总裁。从2001年12月到2006年8月，她曾担任Genzyme General公司（位于马萨诸塞州剑桥）的全球营销副总裁。她领导Myozyme公司（治疗一种超孤儿基因疾病的一个注入酶替代疗法）的全球商业化和计划。她持有康奈尔大学（ Cornell University ，位于纽约伊萨卡）的生物和营养科学的学士学位。
- Julie Anne Smith was appointed as a director and the Chief Executive Officer of the Company, effective January 1 2015. Ms. Smith has also served as President of the Company since July 2014 and CEO-Designate from July 2014 to December 2014.She previously served as our Executive Vice President, Strategy and Chief Operating Officer from 2012 to 2014 where she was responsible for directing our commercial, manufacturing and program management organizations and providing leadership in corporate and strategic development initiatives. In her nearly 20 years in the biotechnology industry, Ms. Smith has served in executive management of both privately- and publicly-held biotechnology firms, mostly in orphan drug development and commercial product opportunities. Prior to joining us, from July 2008 to May 2012 Ms. Smith was Chief Commercial Officer of Enobia Pharma, Inc., a private, clinical-stage orphan drug company acquired by Alexion Pharmaceuticals. From August 2006 to July 2008 she led commercial functions as Vice President, Commercial at Jazz Pharmaceuticals. From December 2001 to August 2006 as Vice President, Global Marketing at Genzyme General in Cambridge, Massachusetts, she led the worldwide commercialization and planning for Myozyme, an infused enzyme replacement therapy for an ultra-orphan genetic disease. She holds a B.S. in Biological and Nutritional Science from Cornell University, Ithaca, New York.
高管简历
中英对照 | 中文 | 英文- Barry S. Ticho
BarryS.Ticho自2017年10月起担任首席医疗官。2016年2月至2017年9月，蒂乔博士担任生物技术公司Moderna，Inc.心血管和代谢疾病主管。从2013年10月到2016年2月，Ticho博士担任辉瑞公司（Pfizer，Inc.）心血管和代谢疾病研究部门的外部研究与开发创新主管。此前，蒂乔博士曾担任生物制药公司BiogenInc.的临床开发Vice President。Ticho博士拥有哈弗福德学院（Haverford College）的生物学学士学位和芝加哥大学（University of Chicago）的生物化学与分子生物学硕士学位和博士学位。
Barry S. Ticho,From March 2018 to March 2019, Dr. Ticho served as the Chief Executive Officer and as a member of the board of directors of Verve Therapeutics, Inc. From February 2016 to September 2017, Dr. Ticho served as Head of Cardiovascular and Metabolic Diseases at Moderna, Inc., a biotechnology company. From October 2013 to February 2016, Dr. Ticho served as Head of External Research and Development Innovation for the Cardiovascular and Metabolic Disease Research Unit at Pfizer, Inc., a pharmaceutical company. Previously, Dr. Ticho served as the Vice President of Clinical Development at Biogen Inc., a biopharmaceutical company. Dr. Ticho holds a B.A. in Biology from Haverford College and an M.D. and a Ph.D. in Biochemistry and Molecular Biology from the University of Chicago.- BarryS.Ticho自2017年10月起担任首席医疗官。2016年2月至2017年9月，蒂乔博士担任生物技术公司Moderna，Inc.心血管和代谢疾病主管。从2013年10月到2016年2月，Ticho博士担任辉瑞公司（Pfizer，Inc.）心血管和代谢疾病研究部门的外部研究与开发创新主管。此前，蒂乔博士曾担任生物制药公司BiogenInc.的临床开发Vice President。Ticho博士拥有哈弗福德学院（Haverford College）的生物学学士学位和芝加哥大学（University of Chicago）的生物化学与分子生物学硕士学位和博士学位。
- Barry S. Ticho,From March 2018 to March 2019, Dr. Ticho served as the Chief Executive Officer and as a member of the board of directors of Verve Therapeutics, Inc. From February 2016 to September 2017, Dr. Ticho served as Head of Cardiovascular and Metabolic Diseases at Moderna, Inc., a biotechnology company. From October 2013 to February 2016, Dr. Ticho served as Head of External Research and Development Innovation for the Cardiovascular and Metabolic Disease Research Unit at Pfizer, Inc., a pharmaceutical company. Previously, Dr. Ticho served as the Vice President of Clinical Development at Biogen Inc., a biopharmaceutical company. Dr. Ticho holds a B.A. in Biology from Haverford College and an M.D. and a Ph.D. in Biochemistry and Molecular Biology from the University of Chicago.
- Thomas E. Leggett
Thomas E. Leggett，于2021年12月至2024年4月期间，在生物技术公司Affinia Therapeutics，Inc.担任首席财务官。Leggett先生还于2019年1月至2021年12月在生物技术公司Black Diamond Therapeutics, Inc.担任首席财务官。在此之前，Leggett先生于2017年1月至2019年8月在生物技术公司Axcella Health，Inc.担任首席财务官。他还曾于2015年5月至2016年12月在制药公司Purdue Pharma LP担任财务主管和业务发展财务主管。Leggett先生还曾在UBS Securities LLC、Lazard Fr è res & Co.和J.P. Morgan Securities Inc.担任越来越多的职务。Leggett先生目前担任Clover Biopharmaceuticals的董事会和提名委员会成员以及审计委员会主席，Clover Biopharmaceuticals是一家开发创新疫苗的商业阶段生物技术公司。Leggett先生拥有哥伦比亚大学经济学学士学位和宾夕法尼亚大学沃顿商学院金融硕士学位。
Thomas E. Leggett,served as the Chief Financial Officer at Affinia Therapeutics, Inc., a biotechnology company, from December 2021 to April 2024. Mr. Leggett also served as the Chief Financial Officer of Black Diamond Therapeutics, Inc., a biotechnology company, from January 2019 to December 2021. Prior to that, Mr. Leggett served as Chief Financial Officer at Axcella Health, Inc., a biotechnology company, from January 2017 to August 2019. He also previously served as Treasurer and Head of Business Development Finance at Purdue Pharma LP, a pharmaceutical company, from May 2015 to December 2016. Mr. Leggett also served in various roles of increasing responsibility at UBS Securities LLC, Lazard Frères & Co., and J.P. Morgan Securities Inc. Mr. Leggett currently serves as a member of the board of directors and nomination committee and as chairman of the audit committee of Clover Biopharmaceuticals, a commercial-stage biotechnology company developing innovative vaccines. Mr. Leggett holds a B.A. in Economics from Columbia University and a M.B.A. in Finance from the Wharton School, University of Pennsylvania.- Thomas E. Leggett，于2021年12月至2024年4月期间，在生物技术公司Affinia Therapeutics，Inc.担任首席财务官。Leggett先生还于2019年1月至2021年12月在生物技术公司Black Diamond Therapeutics, Inc.担任首席财务官。在此之前，Leggett先生于2017年1月至2019年8月在生物技术公司Axcella Health，Inc.担任首席财务官。他还曾于2015年5月至2016年12月在制药公司Purdue Pharma LP担任财务主管和业务发展财务主管。Leggett先生还曾在UBS Securities LLC、Lazard Fr è res & Co.和J.P. Morgan Securities Inc.担任越来越多的职务。Leggett先生目前担任Clover Biopharmaceuticals的董事会和提名委员会成员以及审计委员会主席，Clover Biopharmaceuticals是一家开发创新疫苗的商业阶段生物技术公司。Leggett先生拥有哥伦比亚大学经济学学士学位和宾夕法尼亚大学沃顿商学院金融硕士学位。
- Thomas E. Leggett,served as the Chief Financial Officer at Affinia Therapeutics, Inc., a biotechnology company, from December 2021 to April 2024. Mr. Leggett also served as the Chief Financial Officer of Black Diamond Therapeutics, Inc., a biotechnology company, from January 2019 to December 2021. Prior to that, Mr. Leggett served as Chief Financial Officer at Axcella Health, Inc., a biotechnology company, from January 2017 to August 2019. He also previously served as Treasurer and Head of Business Development Finance at Purdue Pharma LP, a pharmaceutical company, from May 2015 to December 2016. Mr. Leggett also served in various roles of increasing responsibility at UBS Securities LLC, Lazard Frères & Co., and J.P. Morgan Securities Inc. Mr. Leggett currently serves as a member of the board of directors and nomination committee and as chairman of the audit committee of Clover Biopharmaceuticals, a commercial-stage biotechnology company developing innovative vaccines. Mr. Leggett holds a B.A. in Economics from Columbia University and a M.B.A. in Finance from the Wharton School, University of Pennsylvania.
- Jonathan Allan
乔纳森·艾伦（Jonathan Allan）负责监督法律的各个方面，包括就所有法律和合规举措提供领导和指导，并担任斯托克董事会的合规官和公司秘书。在晋升为该职务之前，Allan先生于2021年2月至2022年7月担任Stoke Therapeutics, Inc.副总法律顾问，并于2020年11月至2021年2月担任Stoke Therapeutics, Inc.临时总法律顾问。Allan先生的职业生涯是为处于不同成长阶段的生命科学和技术公司提供法律支持和咨询，并在公司治理、证券和上市公司报告、公司交易、就业事务和知识产权领域带来了特别的专业知识。在加入斯托克之前，Allan先生是Fenwick & West LLP公司集团的合伙人，为一些世界上最具创新性的技术和生命科学公司提供法律支持。在此之前，他曾在Kirkland & Ellis LLP担任企业合伙人，在该公司为多家公共和私人客户提供股东事务和企业交易方面的咨询服务。艾伦先生是纽约律师协会的成员。他拥有俄亥俄州立大学莫里茨法学院的法学博士学位和格雷斯学院的工商管理和市场营销学士学位。
Jonathan Allan,oversees all aspects of legal, including providing leadership and guidance on all legal and compliance initiatives and serving as Compliance Officer and Corporate Secretary to Stoke's Board of Directors. Prior to his promotion to that role, Mr. Allan served as Stoke Therapeutics, Inc. Deputy General Counsel from February 2021 to July 2022 and as Stoke Therapeutics, Inc. Interim General Counsel from November 2020 to February 2021. Before joining Stoke, Mr. Allan was an associate in the corporate group at Fenwick & West LLP, providing legal support to some of the world's most innovative technology and life sciences companies. Prior to that, he served as a corporate associate at Kirkland & Ellis LLP, where he advised a number of public and private clients in shareholder matters and corporate transactions. Mr. Allan is a member of the New York Bar Association. He holds his J.D. from The Ohio State University Moritz College of Law and a B.A. in business administration and marketing from Grace College.- 乔纳森·艾伦（Jonathan Allan）负责监督法律的各个方面，包括就所有法律和合规举措提供领导和指导，并担任斯托克董事会的合规官和公司秘书。在晋升为该职务之前，Allan先生于2021年2月至2022年7月担任Stoke Therapeutics, Inc.副总法律顾问，并于2020年11月至2021年2月担任Stoke Therapeutics, Inc.临时总法律顾问。Allan先生的职业生涯是为处于不同成长阶段的生命科学和技术公司提供法律支持和咨询，并在公司治理、证券和上市公司报告、公司交易、就业事务和知识产权领域带来了特别的专业知识。在加入斯托克之前，Allan先生是Fenwick & West LLP公司集团的合伙人，为一些世界上最具创新性的技术和生命科学公司提供法律支持。在此之前，他曾在Kirkland & Ellis LLP担任企业合伙人，在该公司为多家公共和私人客户提供股东事务和企业交易方面的咨询服务。艾伦先生是纽约律师协会的成员。他拥有俄亥俄州立大学莫里茨法学院的法学博士学位和格雷斯学院的工商管理和市场营销学士学位。
- Jonathan Allan,oversees all aspects of legal, including providing leadership and guidance on all legal and compliance initiatives and serving as Compliance Officer and Corporate Secretary to Stoke's Board of Directors. Prior to his promotion to that role, Mr. Allan served as Stoke Therapeutics, Inc. Deputy General Counsel from February 2021 to July 2022 and as Stoke Therapeutics, Inc. Interim General Counsel from November 2020 to February 2021. Before joining Stoke, Mr. Allan was an associate in the corporate group at Fenwick & West LLP, providing legal support to some of the world's most innovative technology and life sciences companies. Prior to that, he served as a corporate associate at Kirkland & Ellis LLP, where he advised a number of public and private clients in shareholder matters and corporate transactions. Mr. Allan is a member of the New York Bar Association. He holds his J.D. from The Ohio State University Moritz College of Law and a B.A. in business administration and marketing from Grace College.
- Ian F. Smith
Ian F. Smith，是一位经验丰富的领导者，拥有30多年的金融和运营经验。Smith先生目前担任Rivus Pharmaceutical Inc.的董事会主席，他自2023年11月以来一直担任该职位。Smith先生还担任贝恩资本生命科学公司的高级顾问（自2021年1月起担任该职位），以及自2020年6月起担任Solid Biosciences Inc.（纳斯达克：SLDB）董事会执行主席。他还自2021年4月起担任Foghorn Therapeutics Inc.（纳斯达克：FHTX）的董事会成员，并自2023年9月起担任Stoke Therapeutics, Inc.（纳斯达克：STOK）的董事会成员。在担任现任职务之前，Smith先生曾于2019年7月至2022年9月担任私营生物技术公司Viacyte的董事会执行主席。Smith先生此前曾于2001年至2019年1月在福泰制药担任过多个职务，包括首席财务官和首席运营官。在加入福泰制药之前，Smith先生是会计师事务所Ernst & Young LLP的合伙人，为私营和上市公司提供服务，包括生物技术公司。Smith先生还担任多家私营生物技术公司的董事会成员，并提供咨询服务。
Ian F. Smith has served as a member of Odyssey Therapeutics, Inc.'s board of directors since August 2024 and prior to that as a consultant. Mr. Smith is an experienced leader with more than 30 years of finance and operating experience. Mr. Smith has served as Chief Executive Officer of Stoke Therapeutics, Inc. (Nasdaq: STOK) since October 2025 and a member of the board of directors since 2023, and previously served as Interim Chief Executive Officer from March 2025 to October 2025. In addition, Mr. Smith is the Chair of the board of directors for Rivus Pharmaceutical Inc., a position he has held since November 2023. Mr. Smith also serves as a Senior Advisor to Bain Capital Life Sciences, which position he has held since January 2021, and as Executive Chair of the board of directors of Solid Biosciences Inc. (Nasdaq: SLDB), which position he has held since June 2020. He has also served as a member of the board of directors of Foghorn Therapeutics Inc. (Nasdaq: FHTX) since April 2021. Prior to his current roles, Mr. Smith served as Executive Chair of the board of directors of Viacyte, a private biotechnology company, from July 2019 to September 2022. Mr. Smith previously served in various roles at Vertex from 2001 until January 2019, including as the Chief Financial Officer and Chief Operating Officer. Prior to joining Vertex, Mr. Smith was a partner of the accounting firm Ernst & Young LLP, serving private and public companies, including biotechnology companies. Mr. Smith also serves on the boards of a number of private biotechnology companies and provides advisory services. Mr. Smith holds a B.A. with honors in accounting and finance from Manchester Metropolitan University (UK).- Ian F. Smith，是一位经验丰富的领导者，拥有30多年的金融和运营经验。Smith先生目前担任Rivus Pharmaceutical Inc.的董事会主席，他自2023年11月以来一直担任该职位。Smith先生还担任贝恩资本生命科学公司的高级顾问（自2021年1月起担任该职位），以及自2020年6月起担任Solid Biosciences Inc.（纳斯达克：SLDB）董事会执行主席。他还自2021年4月起担任Foghorn Therapeutics Inc.（纳斯达克：FHTX）的董事会成员，并自2023年9月起担任Stoke Therapeutics, Inc.（纳斯达克：STOK）的董事会成员。在担任现任职务之前，Smith先生曾于2019年7月至2022年9月担任私营生物技术公司Viacyte的董事会执行主席。Smith先生此前曾于2001年至2019年1月在福泰制药担任过多个职务，包括首席财务官和首席运营官。在加入福泰制药之前，Smith先生是会计师事务所Ernst & Young LLP的合伙人，为私营和上市公司提供服务，包括生物技术公司。Smith先生还担任多家私营生物技术公司的董事会成员，并提供咨询服务。
- Ian F. Smith has served as a member of Odyssey Therapeutics, Inc.'s board of directors since August 2024 and prior to that as a consultant. Mr. Smith is an experienced leader with more than 30 years of finance and operating experience. Mr. Smith has served as Chief Executive Officer of Stoke Therapeutics, Inc. (Nasdaq: STOK) since October 2025 and a member of the board of directors since 2023, and previously served as Interim Chief Executive Officer from March 2025 to October 2025. In addition, Mr. Smith is the Chair of the board of directors for Rivus Pharmaceutical Inc., a position he has held since November 2023. Mr. Smith also serves as a Senior Advisor to Bain Capital Life Sciences, which position he has held since January 2021, and as Executive Chair of the board of directors of Solid Biosciences Inc. (Nasdaq: SLDB), which position he has held since June 2020. He has also served as a member of the board of directors of Foghorn Therapeutics Inc. (Nasdaq: FHTX) since April 2021. Prior to his current roles, Mr. Smith served as Executive Chair of the board of directors of Viacyte, a private biotechnology company, from July 2019 to September 2022. Mr. Smith previously served in various roles at Vertex from 2001 until January 2019, including as the Chief Financial Officer and Chief Operating Officer. Prior to joining Vertex, Mr. Smith was a partner of the accounting firm Ernst & Young LLP, serving private and public companies, including biotechnology companies. Mr. Smith also serves on the boards of a number of private biotechnology companies and provides advisory services. Mr. Smith holds a B.A. with honors in accounting and finance from Manchester Metropolitan University (UK).